

DAFTAR PUSTAKA

1. Alboni, S., van Dijk, R. M., Poggini, S., Milior, G., Perrotta, M., Drenth, T., Brunello, N., Wolfer, D. P., Limatola, C., Amrein, I., Cirulli, F., Maggi, L., & Branchi, I. (2017). Fluoxetine effects on molecular, cellular and behavioral endophenotypes of depression are driven by the living environment. *Molecular Psychiatry*, 22(4), 552–561. <https://doi.org/10.1038/mp.2015.142>
2. Airaksinen, E., Larsson, M., Lundberg, I., & Forsell, Y. (2004). Cognitive functions in depressive disorders: Evidence from a population-based study. *Psychological Medicine*, 34(1), 83–91. <https://doi.org/10.1017/S0033291703008559>
3. Amir, N. (2006). *Depresi Aspek Neurobiologi Diagnosis dan Tatalaksana*. Balai Penerbit Fakultas Kedokteran Indonesia.
4. Anderson MRCP, I. M. (2000). Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability. In *Journal of Affective Disorders* (Vol. 58). www.elsevier.com/locate/jad
5. Årdal, G., & Hammar, Å. (2011). Is impairment in cognitive inhibition in the acute phase of major depression irreversible? Results from a 10-year follow-up study. *Psychology and Psychotherapy: Theory, Research and Practice*, 84(2), 141–150. <https://doi.org/10.1348/147608310X502328>
6. Association AP. (2015). *DSM-V: Diagnostic and statistical manual of mental disorder Fifth Edition*. CEUR Workshop Proceedings. 2015.
7. Austin MP, M. P. G. G. (2001). Cognitive deficits in depression: Possible implications for functional neuropathology. 2001;178(MARCH.):200–6. *Br J Psychiatry*, 178, 200–206.



beck, A. T. (1976). *Cognitive therapy and the emotional disorders*. International Universities Press.

obo, W. v., Angleró, G. C., Jenkins, G., Hall-Flavin, D. K., Weinshilboum, R., & Biernacka, J. M. (2016). Validation of the 17-

item Hamilton Depression Rating Scale definition of response for adults with major depressive disorder using equipercntile linking to Clinical Global Impression scale ratings: Analysis of Pharmacogenomic Research Network Antidepressant Medication Pharmacogenomic Study (PGRN-AMPS) data. *Human Psychopharmacology*, 31(3), 185–192. <https://doi.org/10.1002/hup.2526>

10. Buckman, J. E. J., Saunders, R., Stott, J., Cohen, Z. D., Arundell, L. L., Eley, T. C., Hollon, S. D., Kendrick, T., Ambler, G., Watkins, E., Gilbody, S., Kessler, D., Wiles, N., Richards, D., Brabyn, S., Littlewood, E., Derubeis, R. J., Lewis, G., & Pilling, S. (2022). Socioeconomic Indicators of Treatment Prognosis for Adults with Depression: A Systematic Review and Individual Patient Data Meta-analysis. In *JAMA Psychiatry* (Vol. 79, Issue 5, pp. 406–416). American Medical Association. <https://doi.org/10.1001/jamapsychiatry.2022.0100>
11. Buckman, J. E. J., Saunders, R., Cohen, Z. D., Barnett, P., Clarke, K., Ambler, G., Derubeis, R. J., Gilbody, S., Hollon, S. D., Kendrick, T., Watkins, E., Wiles, N., Kessler, D., Richards, D., Sharp, D., Brabyn, S., Littlewood, E., Salisbury, C., White, I. R., ... Pilling, S. (2021). The contribution of depressive “disorder characteristics” to determinations of prognosis for adults with depression: An individual patient data meta-analysis. In *Psychological Medicine* (Vol. 51, Issue 7, pp. 1068–1081). Cambridge University Press. <https://doi.org/10.1017/S0033291721001367>

12. Burdick, K. E., Goldberg, T. E., Cornblatt, B. A., Keefe, R. S., Gopin, C. B., Derosse, P., Braga, R. J., & Malhotra, A. K. (2011). The MATRICS consensus cognitive battery in patients with bipolar i sorder. *Neuropsychopharmacology*, 36(8), 1587–1592. <tps://doi.org/10.1038/npp.2011.36>



arniel, B. P., & da Rocha, N. S. (2021). Brain-derived neurotrophic factor (BDNF) and inflammatory markers: Perspectives for the

management of depression. In *Progress in Neuro-Psychopharmacology and Biological Psychiatry* (Vol. 108). Elsevier Inc. <https://doi.org/10.1016/j.pnpbp.2020.110151>

14. Chen, M., & Russo-Neustadt, A. (2017). Norepinephrine Induces BDNF and Activates CREB and Discriminates among Protein Kinase C Isoforms in Cultured Embryonic Hippocampal Neurons. *Neuroscience and Medicine*, 08(04), 53–67. <https://doi.org/10.4236/nm.2017.84008>

15. Cipriani, A., Brambilla, P., Furukawa, T. A., Geddes, J., Gregis, M., Hotopf, M., Malvini, L., & Barbui, C. (2009). Fluoxetine versus other types of pharmacotherapy for depression. In *Cochrane Database of Systematic Reviews* (Issue 4). John Wiley and Sons Ltd. <https://doi.org/10.1002/14651858.CD004185.pub2>

16. Cohen, R., Lohr, I., Robert Paul, M., & Boland, R. (2001). Impairments of Attention and Effort Among Patients with Major Affective Disorders. In *The Journal of Neuropsychiatry and Clinical Neurosciences* (Vol. 13).

17. Collier Villaume, S., Chen, S., & Adam, E. K. (2023). Age Disparities in Prevalence of Anxiety and Depression among US Adults during the COVID-19 Pandemic. *JAMA Network Open*, 6(11), E2345073. <https://doi.org/10.1001/jamanetworkopen.2023.45073>

18. Cooke, J. D., Cavender, H. M., Lima, H. K., & Grover, L. M. (2014). Antidepressants that inhibit both serotonin and norepinephrine reuptake impair long-term potentiation in hippocampus. *Psychopharmacology*, 231(23), 4429–4441. <https://doi.org/10.1007/s00213-014-3587-1>

19. Coppell, A. L., Pei, Q., & Zetterström, T. S. C. (2003). Bi-phasic change in BDNF gene expression following antidepressant drug treatment. *Neuropharmacology*, 44(7), 903–910. [https://doi.org/10.1016/S0028-3908\(03\)00077-7](https://doi.org/10.1016/S0028-3908(03)00077-7)

Correia, A. S., Cardoso, A., & Vale, N. (2023). Oxidative Stress in Depression: The Link with the Stress Response, Neuroinflammation,



- Serotonin, Neurogenesis and Synaptic Plasticity. In *Antioxidants* (Vol. 12, Issue 2). MDPI. <https://doi.org/10.3390/antiox12020470>
21. de Jonghe, F., Ravelli, D. P., & Tuynman-Qua, H. (1991). *A Randomized, Double-Blind Study of Fluoxetine and Maprotiline in the Treatment of Major Depression*.
22. Dean, J., & Keshavan, M. (2017). The neurobiology of depression: An integrated view. In *Asian Journal of Psychiatry* (Vol. 27, pp. 101–111). Elsevier B.V. <https://doi.org/10.1016/j.ajp.2017.01.025>
23. Dong, L., Xu, L., Li, Y., Lv, Y., Liu, H., Li, Y., Xu, F., Wu, J., Zheng, Q., & Li, L. (2018). Model-based comparing efficacy of fluoxetine between elderly and non-elderly participants with major depressive disorder. *Journal of Affective Disorders*, 229, 224–230. <https://doi.org/10.1016/j.jad.2017.12.103>
24. Egan, M. F., Kojima, M., Callicott, J. H., Goldberg, T. E., Kolachana, B. S., Bertolino, A., Zaitsev, E., Gold, B., Goldman, D., Dean, M., Lu, B., & Weinberger, D. R. (2003). The BDNF val66met Polymorphism Affects Activity-Dependent Secretion of BDNF and Human Memory and Hippocampal Function and its val/met polymorphism in human memory and hippocampal function and suggest val/met exerts these effects by impacting intracellular trafficking and activity-dependent secretion of BDNF. In *Cell* (Vol. 112).
25. Elvira, S. D.; G. H. (2017). *Buku Ajar Psikiatri Edisi 3*. Badan penerbit FKUI.
26. Erickson, K. I., Miller, D. L., & Roecklein, K. A. (2012). The aging hippocampus: Interactions between exercise, depression, and BDNF. In *Neuroscientist* (Vol. 18, Issue 1, pp. 82–97). <https://doi.org/10.1177/1073858410397054>
27. Femenía, T., Gómez-Galán, M., Lindskog, M., & Magara, S. (2012). Dysfunctional hippocampal activity affects emotion and cognition in mood disorders. In *Brain Research* (Vol. 1476, pp. 58–70). <https://doi.org/10.1016/j.brainres.2012.03.053>



28. Fossati, P., Coyette, F., Ergis, A.-M., & Allilaire, J.-F. (2002). Influence of age and executive functioning on verbal memory of inpatients with depression. In *Journal of Affective Disorders* (Vol. 68). www.elsevier.com/locate/jad
29. Frank, J. D. (1971). *Eleventh Emil A. Gutheil Memorial Conference Therapeutic Factors in Psychotherapy**.
30. Gatt, J. M., Nemeroff, C. B., Dobson-Stone, C., Paul, R. H., Bryant, R. A., Schofield, P. R., Gordon, E., Kemp, A. H., & Williams, L. M. (2009). Interactions between BDNF Val66Met polymorphism and early life stress predict brain and arousal pathways to syndromal depression and anxiety. *Molecular Psychiatry*, 14(7), 681–695. <https://doi.org/10.1038/mp.2008.143>
31. Guo, W. bin, Liu, F., Xue, Z. M., Yu, Y., Ma, C. Q., Tan, C. L., Sun, X. L., Chen, J. D., Liu, Z. N., Xiao, C. Q., Chen, H. F., & Zhao, J. P. (2011). Abnormal neural activities in first-episode, treatment-naïve, short-illness-duration, and treatment-response patients with major depressive disorder: A resting-state fMRI study. *Journal of Affective Disorders*, 135(1–3), 326–331. <https://doi.org/10.1016/j.jad.2011.06.048>
32. Hajós, M., Fleishaker, J. C., Filipiak-Reisner, J. K., Brown, M. T., & Wong, E. H. F. (2004). The Selective Norepinephrine Reuptake Inhibitor Antidepressant Reboxetine: Pharmacological and Clinical Profile. In *CNS Drug Reviews* (Vol. 10, Issue 1, pp. 23–44). Neva Press Inc. <https://doi.org/10.1111/j.1527-3458.2004.tb00002.x>
33. Hajszan, T., MacLusky, N. J., & Leranth, C. (2005). Short-term treatment with the antidepressant fluoxetine triggers pyramidal dendritic spine synapse formation in rat hippocampus. *European Journal of Neuroscience*, 21(5), 1299–1303. [tps://doi.org/10.1111/j.1460-9568.2005.03968.x](https://doi.org/10.1111/j.1460-9568.2005.03968.x)
- andawati Wijaya, S., Tannika, A., & Hudyono, J. (2019). Peranan token pada Keadaan Stres sebagai Pencetus Depresi Role of



Cytokines in Stressful Condition as A Trigger for A Depression. In *Jurnal Penyakit Dalam Indonesia* | (Vol. 6, Issue 4).

35. Harold I Kaplan and Benjamin J Sadock. (1995). *Comprehensive Textbook of Psychiatry*/VI. Waverly Europe, London.
 36. Hashimoto, K. (2010). *Brain-derived neurotrophic factor as a biomarker for mood disorders: An historical overview and future directions* *pn_2113 341.357*.
 37. Hellweg, R., Ziegenhorn, A., Heuser, I., & Deuschle, M. (2008). Serum concentrations of nerve growth factor and brain-derived neurotrophic factor in depressed patients before and after antidepressant treatment. *Pharmacopsychiatry*, 41(2), 66–71. <https://doi.org/10.1055/s-2007-1004594>
 38. Herlenius, E., & Lagercrantz, H. (2001). *Neurotransmitters and neuromodulators during early human development*. www.elsevier.com/locate/earlhumdev
 39. Homberg, J. R., Molteni, R., Calabrese, F., & Riva, M. A. (2014). The serotonin-BDNF duo: Developmental implications for the vulnerability to psychopathology. In *Neuroscience and Biobehavioral Reviews* (Vol. 43, pp. 35–47). Elsevier Ltd. <https://doi.org/10.1016/j.neubiorev.2014.03.012>
 40. Khan, M. S., Wu, G. W. Y., Reus, V. I., Hough, C. M., Lindqvist, D., Westrin, Å., Nier, B. M., Wolkowitz, O. M., & Mellon, S. H. (2019). Low serum brain-derived neurotrophic factor is associated with suicidal ideation in major depressive disorder. *Psychiatry Research*, 273, 108–113. <https://doi.org/10.1016/j.psychres.2019.01.013>
 41. Kroeze, Y., Zhou, H., & Homberg, J. R. (2012). The genetics of selective serotonin reuptake inhibitors. In *Pharmacology and Therapeutics* (Vol. 136, Issue 3, pp. 375–400). Elsevier Inc. [tps://doi.org/10.1016/j.pharmthera.2012.08.015](https://doi.org/10.1016/j.pharmthera.2012.08.015)
- umar, V. A. J. C. A. K. A. (2018). *Robbins Basic Pathology, 10th Ed: ol. 10th Ed*. Philadelphia: Elsevier., 2018.



43. Kusumawardhani AAAA, Amir N. et al. (2013). *Panduan Tatalaksana Gangguan Depresi Mayor*. PP PDSKJI.
44. LaBar, K. S., & Cabeza, R. (2006). Cognitive neuroscience of emotional memory. In *Nature Reviews Neuroscience* (Vol. 7, Issue 1, pp. 54–64). <https://doi.org/10.1038/nrn1825>
45. Lam RW, K. S. M. R. K. A. (2014). Cognitive dysfunction in depression -psychosocial functioning. *Can J Psychiatry.*, 59, 649–654.
46. Lee, B. H., Kim, H., Park, S. H., & Kim, Y. K. (2007). Decreased plasma BDNF level in depressive patients. *Journal of Affective Disorders*, 101(1–3), 239–244. <https://doi.org/10.1016/j.jad.2006.11.005>
47. Li, G., Jing, P., Liu, Z., Li, Z., Ma, H., Tu, W., Zhang, W., & Zhuo, C. (2017). Beneficial effect of fluoxetine treatment against psychological stress is mediated by increasing BDNF expression in selected brain areas. In *Oncotarget* (Vol. 8, Issue 41). www.impactjournals.com/oncotarget/
48. Lommatzsch, M., Zingler, D., Schuhbaeck, K., Schloetcke, K., Zingler, C., Schuff-Werner, P., & Virchow, J. C. (2005). The impact of age, weight and gender on BDNF levels in human platelets and plasma. *Neurobiology of Aging*, 26(1), 115–123. <https://doi.org/10.1016/j.neurobiolaging.2004.03.002>
49. Lu, B., Nagappan, G., & Lu, Y. (2015). BDNF and synaptic plasticity, cognitive function, and dysfunction. *Handbook of Experimental Pharmacology*, 220, 223–250. https://doi.org/10.1007/978-3-642-45106-5_9
50. Magni, L. R., Purgato, M., Gastaldon, C., Papola, D., Furukawa, T. A., Cipriani, A., & Barbui, C. (2013). Fluoxetine versus other types of pharmacotherapy for depression. In *Cochrane Database of Systematic Reviews* (Vol. 2013, Issue 7). John Wiley and Sons Ltd. <https://doi.org/10.1002/14651858.CD004185.pub3>
- akizako, H., Liu-Ambrose, T., Shimada, H., Doi, T., Park, H., Iwamoto, K., Uemura, K., & Suzuki, T. (2015). Moderate-



intensity physical activity, hippocampal volume, and memory in older adults with mild cognitive impairment. *Journals of Gerontology - Series A Biological Sciences and Medical Sciences*, 70(4), 480–486. <https://doi.org/10.1093/gerona/glu136>

52. Maletic, V., Robinson, M., Oakes, T., Iyengar, S., Ball, S. G., & Russell, J. (2007). Neurobiology of depression: An integrated view of key findings. In *International Journal of Clinical Practice* (Vol. 61, Issue 12, pp. 2030–2040). <https://doi.org/10.1111/j.1742-1241.2007.01602.x>

53. Martenyi, F., Dossenbach, M., Mraz, K., & Metcalfe, S. (2001). Gender differences in the efficacy of fluoxetine and maprotiline in depressed patients: a double-blind trial of antidepressants with serotonergic or norepinephrinergic reuptake inhibition profile. In *European Neuropsychopharmacology* (Vol. 11). www.elsevier.com/locate/euroneuro

54. Maslim Rusdi. (2019). Gangguan Suasana Hati. In: *Diagnosis Gangguan Jiwa (PPDGJ-III)*. (3th ed). Bagian Ilmu Kedokteran Jiwa FK-Unika Atma Jaya.

55. Maurizio Fava, & Lesley M Graves, F. B. M. J. S. D. V. I. J. E. A. G. I. P. (2006). A cross-sectional study of the prevalence of cognitive and physical symptoms during long-term antidepressant treatment. *J Clin Psychiatry*. 2006 Nov;67(11):1754-9., 67, 1754–1759.

56. Moncrieff, J., Cooper, R. E., Stockmann, T., Amendola, S., Hengartner, M. P., & Horowitz, M. A. (2023). The serotonin theory of depression: a systematic umbrella review of the evidence. In *Molecular Psychiatry* (Vol. 28, Issue 8, pp. 3243–3256). Springer Nature. <https://doi.org/10.1038/s41380-022-01661-0>

57. Moret, C., & Briley, M. (2011). The importance of norepinephrine in depression. *Neuropsychiatric Disease and Treatment*, 7(SUPPL.), 9–13. <https://doi.org/10.2147/NDT.S19619>

Mosiółek, A., Pięta, A., Jakima, S., Zborowska, N., Mosiółek, J., & Sulc, A. (2021). Effects of antidepressant treatment on peripheral



biomarkers in patients with major depressive disorder (Mdd). In *Journal of Clinical Medicine* (Vol. 10, Issue 8). MDPI. <https://doi.org/10.3390/jcm10081706>

59. Mumang, A. A., Syamsuddin, S., Maria, I. L., & Yusuf, I. (2021). Gender Differences in Depression in the General Population of Indonesia: Confounding Effects. *Depression Research and Treatment*, 2021. <https://doi.org/10.1155/2021/3162445>
60. Oral, E., Canpolat, S., Yildirim, S., Gulec, M., Aliyev, E., & Aydin, N. (2012). Cognitive functions and serum levels of brain-derived neurotrophic factor in patients with major depressive disorder. *Brain Research Bulletin*, 88(5), 454–459. <https://doi.org/10.1016/j.brainresbull.2012.03.005>
61. Patria, B. (2022) 'The longitudinal effects of education on depression: Finding from the Indonesian national survey', *Frontiers in Public Health*, 10. Available at: <https://doi.org/10.3389/fpubh.2022.1017995>.
62. Patterson, S. L. (2015). Immune dysregulation and cognitive vulnerability in the aging brain: Interactions of microglia, IL-1 β , BDNF and synaptic plasticity. In *Neuropharmacology* (Vol. 96, Issue PA, pp. 11–18). Elsevier Ltd. <https://doi.org/10.1016/j.neuropharm.2014.12.020>
63. Perez-Caballero, L., Torres-Sanchez, S., Bravo, L., Mico, J. A., & Berrocoso, E. (2014). Fluoxetine: A case history of its discovery and preclinical development. In *Expert Opinion on Drug Discovery* (Vol. 9, Issue 5, pp. 567–578). Informa Healthcare. <https://doi.org/10.1517/17460441.2014.907790>
64. Peveler, R., Carson, A., & Rodin, G. (2003). *ABC of psychological medicine Depression in medical patients*.
65. Phillips, C. (2017). Brain-Derived Neurotrophic Factor, Depression, and Physical Activity: Making the Neuroplastic Connection. In *Neural Plasticity* (Vol. 2017). Hindawi Limited. <https://doi.org/10.1155/2017/7260130>



66. Piccinni, A., Marazziti, D., Catena, M., Domenici, L., del Debbio, A., Bianchi, C., Mannari, C., Martini, C., da Pozzo, E., Schiavi, E., Mariotti, A., Roncaglia, I., Palla, A., Consoli, G., Giovannini, L., Massimetti, G., & Dell'Osso, L. (2008). Plasma and serum brain-derived neurotrophic factor (BDNF) in depressed patients during 1 year of antidepressant treatments. *Journal of Affective Disorders*, 105(1–3), 279–283. <https://doi.org/10.1016/j.jad.2007.05.005>
67. Pinder, R. M., Brogden, R. N., Speight, T. M., & Very, G. S. A. (1977). Evaluations on New Drugs Maprotiline: A Review of its Pharmacological Properties and Therapeutic Efficacy in Mental Depressive States. In *Drugs* (Vol. 13).
68. Rasmussen, P., Brassard, P., Adser, H., Pedersen, M. v., Leick, L., Hart, E., Secher, N. H., Pedersen, B. K., & Pilegaard, H. (2009). Evidence for a release of brain-derived neurotrophic factor from the brain during exercise. *Experimental Physiology*, 94(10), 1062–1069. <https://doi.org/10.1113/expphysiol.2009.048512>
69. Reyad, A. A., Plaha, K., Girgis, E., & Mishriky, R. (2021). Fluoxetine in the Management of Major Depressive Disorder in Children and Adolescents: A Meta-Analysis of Randomized Controlled Trials. *Hospital Pharmacy*, 56(5), 525–531. <https://doi.org/10.1177/0018578720925384>
70. Roche, A. M., Pidd, K., Fischer, J. A., Lee, N., Scarfe, A., & Kostadinov, V. (2016). Men, Work, and Mental Health: A Systematic Review of Depression in Male-dominated Industries and Occupations. In *Safety and Health at Work* (Vol. 7, Issue 4, pp. 268–283). Elsevier Science B.V. <https://doi.org/10.1016/j.shaw.2016.04.005>
71. Sabic, D., Sabic, A., & Bacic-Becirovic, A. (2021). Major Depressive disorder and Difference between Genders. *Materia Socio-Medica*, 3(2), 105–108. <https://doi.org/10.5455/msm.2021.33.105-108>



72. Sadock, B. J.; S. V. A.; et al., (2017). *Mood Disorders in Comprehensive Textbook of Psychiatry, Vol. Volume I/II* (10th edition.). Wolters Kluwer.
73. Santi, N. S., Biswal, S. B., Naik, B. N., Sahoo, J. P., & Rath, B. (2023). Comparison of Hamilton Depression Rating Scale and Montgomery-Åsberg Depression Rating Scale: Baked Straight From a Randomized Study. *Cureus*. <https://doi.org/10.7759/cureus.45098>
74. Staats, R., Stoll, P., Zingler, D., Virchow, J. C., & Lommatzsch, M. (2005). Regulation of brain-derived neurotrophic factor (BDNF) during sleep apnoea treatment. *Thorax*, 60(8), 688–692. <https://doi.org/10.1136/thx.2004.038208>
75. Stefanovski, B., Novotni, A., Marinov, P., & Profile, S. (2013). *Different serum BDNF levels in depression: results from BDNF studies in FYR Macedonia and Bulgaria*. <https://www.researchgate.net/publication/241693506>
76. Stephen M Stahl (2021). *Mood Disorders in Stahl's Essential Psychopharmacology, Neuroscientific Basis and Practical Application*, (Vol. 5th). Cambridge University Press.
77. Tang, S. W., Chu, E., Hui, T., Helmeste, D., & Law, C. (2008). Influence of exercise on serum brain-derived neurotrophic factor concentrations in healthy human subjects. *Neuroscience Letters*, 431(1), 62–65. <https://doi.org/10.1016/j.neulet.2007.11.019>
78. Trivedi, M. H., & Greer, T. L. (2014). Cognitive dysfunction in unipolar depression: Implications for treatment. In *Journal of Affective Disorders* (Vols. 152–154, Issue 1, pp. 19–27). <https://doi.org/10.1016/j.jad.2013.09.012>
79. Vaynman, S., Ying, Z., & Gomez-Pinilla, F. (2004). Hippocampal BDNF mediates the efficacy of exercise on synaptic plasticity and cognition. *European Journal of Neuroscience*, 20(10), 2580–2590. <https://doi.org/10.1111/j.1460-9568.2004.03720.x>



80. World Health Organization. (1992). *The ICD-10 classification of mental and behavioural disorders: clinical descriptions and diagnostic guidelines*. World Health Organization.
81. World Health Organization. (2023, March 31). *Depressive disorder (depression)*. <https://www.who.int/news-room/fact-sheets/detail/depression>
82. Yavuz, A. E., Haman Bayari, S., & Kazanci, N. (2009). Structural and vibrational study of maprotiline. *Journal of Molecular Structure*, 924–926(C), 313–321. <https://doi.org/10.1016/j.molstruc.2008.11.029>
83. Zarate, C., Duman, R. S., Liu, G., Sartori, S., Quiroz, J., & Murck, H. (2013). New paradigms for treatment-resistant depression. *Annals of the New York Academy of Sciences*, 1292(1), 21–31. <https://doi.org/10.1111/nyas.12223>

